Advances in Multiple Myeloma: Insights from Experts at Emory University on Translating Evidence to Clinical Practice

An overview of the currently available frontline treatment options for transplant-eligible multiple myeloma.

A review of the study design and results of two clinical trials researching quadruplet therapies for newly diagnosed multiple myeloma presented at ASH 2021.

Experts discuss how they select a treatment regimen for a newly diagnosed multiple myeloma patient, and how they measure a successful treatment response.

Drs Ajay Nooka and Jonathan Kaufman discuss maintenance and consolidation treatment strategies for transplant eligible multiple myeloma.

Dr Nisha Joseph presents the case of a woman with transplant-ineligible multiple myeloma and discusses considerations when choosing frontline treatment regimens.

An overview of the study design, efficacy, and safety findings of the MAIA trial.

Experts discuss how they define frail and high-risk patients with multiple myeloma and their treatment approaches for these patient populations.

Nisha Joseph, MD, presents the case of a 78-year-old man with transplant-ineligible multiple myeloma and discusses treatment strategy.

Key opinion leaders describe the role of blood-based MRD testing in the transplant-ineligible multiple myeloma treatment landscape.

Experts discuss the case of a woman with relapsed/refractory multiple myeloma and the available treatment options, including novel BCMA-targeted agents.

A look at the role of bispecifics and CAR T-cell therapies in the multiple myeloma treatment landscape.

Experts muse on the unmet needs of multiple myeloma, and exciting investigational therapies on the horizon.

A panel of experts from Emory University review several key data updates in multiple myeloma from recent meetings and discuss how the data can be applied to clinical practice to improve patient outcomes.